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ess: david.sistek@hospvSummary Respiratory symptoms are often used as the only diagnostic criteria for
asthma in epidemiological surveys and the clinical diagnosis of asthma relies primarily on
a detailed history. The aim of this study is to predict the diagnostic value of 11 different
respiratory symptoms to diagnose asthma, and to determine if bronchial hyperrespon-
siveness (BHR) improves the predictive value of these respiratory symptoms.
A random sample of 1257 subjects aged 20–44 years old in 3 different areas of New
Zealand were selected between March 1991 and December 1992 to answer the European
Community Respiratory Health Survey questionnaire on respiratory symptoms. Of these,
784 underwent bronchial challenge with methacholine. The prevalence of current
doctor diagnosed asthma (DDA) defined as asthma confirmed by a physician and an
asthma attack in the last 12 months was 8.3%. Wheezing with dyspnoea is the single best
predictor of diagnosed asthma with a sensitivity of 82%, a specificity of 90% and a
Youden’s index of 0.72. Wheezing alone is more sensitive (94%) but less specific (76%),
with a Youden’s index of 0.70. The addition of BHR to asthma symptoms decreases
sensitivity and increases specificity with a small increase in Youden’s index to 0.75. In
New Zealand adults, a history of wheezing with BHR best predicts a diagnosis of asthma
but wheezing alone or with dyspnoea are the two best symptoms for predicting asthma.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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As discussed by Boushey et al.,1 there is no
universally agreed definition of asthma. A consen-
sus ‘‘definition’’ is based on description of features
such as respiratory symptoms, variable airflow
obstruction, airway pathology and physiological
abnormalities, such as bronchial hyperresponsive-
ness (BHR). In clinical practice, the diagnosis
of asthma is principally based on a history of
respiratory symptoms together with evidence of
airway obstruction measured by daily peak expira-
tory flow variability or by an increase in FEV1 after
b2 agonist. In some cases the diagnosis of asthma is
difficult and may require further investigation such
as BHR or a response to corticosteroids.
Large-scale international studies of asthma pre-
valence have recently been undertaken in adults
and children. These studies have developed stan-
dardised questionnaires and protocols. The Eur-
opean Community Respiratory Health Survey
(ECRHS),2 a multicentre study of asthma demon-
strated that the highest prevalence of asthma and
respiratory symptoms was in English speaking
countries (Australia, New Zealand, UK). During
the same period, another large study (SAPALDIA
study)3 measured the prevalence of asthma and
respiratory symptoms in five different areas of
Switzerland using the ECRHS study questionnaires.
We have used the New Zealand ECRHS study data
to explore the relationships between reported
respiratory symptoms and a doctor’s diagnosis of
asthma and made informal comparisons with the
SAPALDIA study.4Methods
A random sample of 2004 adults, aged 20–44 years,
in Hawkes Bay, Wellington and Christchurch were
randomly selected from the ECRHS Phase I study
which was undertaken in New Zealand between
March 1991 and December 1992. One thousand two
hundred and fifty-seven subjects participated in
Phase II by completing a questionnaire on respira-
tory symptoms and 784 of those subjects (62.3%)
underwent a methacholine challenge. The details
of the method are described elsewhere.5 Briefly,
after initial baseline measurement of FEV1, sub-
jects had four inhalations of diluent (0.9% sodium
chloride with 3ml neutral sodium phosphate
buffer) and a control FEV1 was measured after
2min. Subjects then inhaled increasing doses of
methacholine with repeat measurement of FEV1.
Individuals were classified, as having BHR if theprovocative dose causing a 20% fall in FEV1 was
equal or less than 1mg.Statistics
Data were analysed using PC SAS version 8 (SAS
Institute Inc., Cary, NC, USA). All analysis was
restricted to the 784 subjects who underwent the
methacholine challenge. Sensitivity (S) is the
frequency of positive predictor values among
subjects with the disease. Specificity (SP) is the
frequency of negative predictor values among
subjects without the disease. The Youden index
(J) evaluates the diagnostic efficacy of a predictor.
It is expressed as the sum of the sensitivity and the
specificity minus one (J ¼ S+SP1). The closer
the index is to 1 the better is the diagnostic value.
The positive predictive value (PPV) is the prob-
ability that the subject has the disease when the
predictor is positive. The negative predictive value
(NPV) is the probability that the subject does not
have the disease when the predictor is negative. A
predictor may be a clinical test (i.e. BHR) or a
respiratory symptom or a combination of both.
Gender differences in the predictive value of each
symptom for doctor diagnosed asthma (DDA) were
determined using the Breslow Day test for homo-
geneity. A minimum set of symptoms which
independently predicted asthma was estimated
using the backwards selection option of the logistic
procedure in SAS, after adjustment for gender, age,
ethnicity (Maori, Pacific Island, European/Other)
and current smoking.Asthma and respiratory symptoms definitions
DDA was defined as a positive answer to all the
three following questions: ‘‘Have you ever had
asthma?,’’ ‘‘Was this (asthma) confirmed by a
doctor?’’ and ‘‘Have you had an attack of asthma
in the last 12 months?’’. The symptoms were
defined as a positive answer to the following
questions:
Wheezing (W) was ‘‘Have you had wheezing or
whistling in your chest at any time in the last 12
months?’’ Wheezing with dyspnoea (WwD) was
‘‘Have you been at all breathless when the
wheezing noise was present?’’ Wheezing without a
cold (WwC) was ‘‘Have you had this wheeze or
whistling when you did not have a cold?’’ Nocturnal
dyspnoea (ND) was ‘‘Have you been woken up by an
attack of shortness of breath at any time in the last
12 months?’’ Nocturnal chest tightness (NCT) was
‘‘Have you woken up with a feeling of tightness in
your chest at any time in the last 12 months?’’
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up by an attack of coughing at any time in the last
12 months?’’. Rest dyspnoea (RD) was ‘‘Have you
had an attack of shortness of breath that came on
during the day when you were at rest at any time in
the last 12 months?’’ Exercise dyspnoea (ED) was
‘‘Have you had an attack of shortness of breath that
came on following strenuous activity at any time in
the last 12 months?’’ Chronic cough (CC) was ‘‘Do
you usually cough during the day, or at night, in the
winter?’’ Chronic phlegm (CP) was ‘‘Do you usually
bring up any phlegm from your chest in the morning
in the winter?’’ Chronic bronchitis (CB) was either
CC and/or CP. Nocturnal symptoms (NS) was NC
and/or NCT and/or ND.
The study was approved by the then Ethics
Committees of the Wellington Area Health Board,
Canterbury Area Health Board and the Hawke’s Bay
Area Health Board.Results
Of the 1257 subjects who took part in Phase 2 of the
ECRHS, 784 attended the laboratory and underwent
methacholine challenge. Completing the question-
naire was the minimum requirement for inclusion in
Phase 2 and a number of subjects refused to attend
and completed the questionnaire by phone. How-
ever there were no differences in symptom
prevalence between those who underwent metha-
choline challenge and those who did not (resultsTable 1 Predictive value of respiratory symptoms (in th
Prevalence
(%)
Sensitivity
(%)
Specific
(%)
BHR 24.9 84.6 80.5
W 29.5 93.9 76.4
WwD 15.8 81.5 90.1
WwC 18.5 76.9 86.8
ND 7.3 41.5 95.8
NCT 19.9 75.4 85.1
NC 36.1 60.0 66.1
RD 10.1 43.1 92.9
ED 27.8 75.4 76.5
CC 18.4 43.1 83.9
CP 12.9 26.2 88.3
CB 8.0 21.5 93.2
NS 44.1 83.1 59.4
BHR ¼ bronchial hyperresponsiveness; PPV ¼ positive predictive
W ¼ wheezing; WwD ¼ wheezing with dyspnoea; WwC ¼ wheezi
chest tightness; NC ¼ nocturnal cough; RD ¼ rest dyspnoea; E
phlegm; CB ¼ chronic bronchitis; NS ¼ nocturnal symptoms ¼ NDnot shown). We have therefore undertaken all
further analyses on those who had the challenge
test. Out of the 784 subjects who underwent the
BHR challenge, the mean age was 34.6 years, 54%
were male, 6% Maori, 2% Pacific Island and 92% had
European or Other ethnicity. 8.3% had a DDA, and
29.5% reported wheezing in the last 12 months. The
prevalence of BHR was 24.9%.
Table 1 shows the predictive value of BHR and
respiratory symptoms for diagnosed asthma. BHR
alone has both high sensitivity (84.6%) and speci-
ficity (80.5%) but a low PPV (28.2%) for DDA.
Wheezing had the highest sensitivity (93.9%) but a
lower specificity (76.4%) and a similar PPV (26.4%)
to BHR. WwD and ND have high specificity (over
90%) but lower sensitivity (WwD: 81.5%, ND: 41.5%)
and PPV (over 40%). All the symptoms have a good
NPV (over 93%). Wheezing with dyspnoea and
wheezing alone have the highest Youden’s index,
0.72 and 0.70 respectively. There were significant
gender differences in the predictive power of some
symptoms, with the Youden Index higher for
females than males for NST (0.73 vs 0.46), CC
(0.50 vs 0.01), CP (0.26 vs 0.01) and CB (0.28 vs
0.01) but among females only NST was a good
predictor of doctor’s diagnosed asthma. After
adjusting all symptoms in a combined model for
age, gender, ethnicity and current smoking,
wheeze, wheeze with dyspnoea, nocturnal dys-
pnoea, NCT and ED remained strong and significant
predictors of asthma.
Table 2, shows the predictive value of respiratory
symptoms in association with BHR for diagnosede last 12 months) and BHR to predict DDA (n ¼ 784)
ity PPV
(%)
NPV
(%)
Youden
index
28.2 98.3 0.65
26.4 99.3 0.70
42.7 98.2 0.72
34.5 97.7 0.64
47.4 94.8 0.37
31.4 97.5 0.61
13.8 94.8 0.26
35.4 94.8 0.36
22.5 97.2 0.52
19.4 94.2 0.27
16.8 93.0 0.15
22.2 92.9 0.15
15.6 97.5 0.43
value; NPV ¼ negative predictive value.
ng without cold; ND ¼ nocturnal dyspnoea; NCT ¼ nocturnal
D ¼ exercise dyspnoea; CC ¼ chronic cough; CP ¼ chronic
and/or NC and/or NCT.
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Table 2 Predictive values of respiratory symptoms (in the last 12 months) in association with BHR to predict
DDA (n ¼ 784)
Prevalence
(%)
Sensitivity
(%)
Specificity
(%)y
PPV
(%)
NPV
(%)
Youden
index
W and BHR 14.2 83.1 92.1 48.7 98.4 0.75
WwD and BHR 9.6 72.3 96.1 62.7 97.5 0.68
WwC and BHR 10.3 66.2 94.7 53.1 96.9 0.61
ND and BHR 4.6 38.5 98.5 69.4 94.7 0.37
NCT and BHR 10.0 66.2 95.1 55.1 96.9 0.61
NC and BHR 12.0 52.3 91.7 36.2 91.7 0.44
RD and BHR 4.6 33.9 98.1 61.1 94.3 0.32
ED and BHR 10.6 63.1 94.2 49.4 96.6 0.57
CC and BHR 7.3 36.9 95.4 42.1 94.4 0.32
CP and BHR 5.1 23.1 96.5 37.5 93.3 0.20
CB and BHR 3.7 20 97.8 44.8 93.1 0.18
NS and BHR 15.3 70.8 89.7 38.3 97.1 0.61
For abbreviations see Table 1.
Compared to Table 1, the sensitivity was significantly lower (Po0:05) for all symptoms apart from ND, CP and CB.
yCompared to Table 1, the specificity was significantly higher (Po0:0001) for all symptoms.
D. Sistek et al.2110asthma. In general the addition of BHR to symptoms
tends to decrease sensitivity and increase specifi-
city. Wheezing with BHR has the highest Youden’s
index, 0.75. All respiratory symptoms with BHR
(apart from NS) have a high specificity for DDA. ND
and WwD with positive BHR have the highest PPV
(respectively 69.4% and 62.7%).Discussion
As shown in a previous study6 New Zealand has one
of the highest prevalence rates of asthma in the
world. Compared to a Swiss study (SAPALDIA Study)
of respiratory symptoms4 which took place at the
same period of time, used the same questionnaire
on respiratory symptoms (ECRHS) and the same
definition of asthma, New Zealand has a prevalence
of current DDA 3.5-fold higher than Switzerland
(8.3% versus 2.3%). In New Zealand, all symptoms
have a higher sensitivity for DDA than in Switzer-
land, except for nocturnal (ND) and rest dyspnoea
(RD). Specificity is similar in the two studies. PPV
and NPV are difficult to compare because of the
great difference in asthma prevalence in the two
countries. This closer association between obstruc-
tive respiratory symptoms and the diagnosis of
asthma seen in New Zealand could be that the
physician diagnosing asthma pays greater attention
to these symptoms than in Switzerland. Because of
a higher prevalence of asthma in New Zealand,
general practitioners are probably more aware ofthe disease, and perhaps more willing to apply the
label asthma to these respiratory symptoms.
Another explanation could be that in English
speaking countries the word ‘‘wheeze’’ could have
a closer association with a diagnosis of asthma than
in other languages. Interestingly dyspnoea at rest
and at night have similar sensitivity for the
diagnosis. Jenkins et al.7 validated a respiratory
questionnaire against respiratory physician diag-
nosed asthma in Australia. They found a sensitivity
of 80% and a specificity of 97% for wheezing or
attack of asthma in the last 12 months. These
Australian results are similar to the SAPALDIA study
but the sensitivity of wheezing for physician-
diagnosed asthma is still lower than in New Zealand
despite both being English speaking countries.
However, in the Jenkins study the diagnosis was
made by respiratory physicians rather than general
practitioners.
Our results show a great difference in prevalence
between current wheezing (28.5%) and DDA (8.3%).
DDA probably underestimates the prevalence of
asthma. Subjects with intermittent self-resolving
wheezing will probably not consult their doctor.
Alternatively self-reported wheezing will overesti-
mate the prevalence of asthma and include for
example, smokers with or without chronic obstruc-
tive pulmonary disease or subjects with post-viral
wheeze or bacterial bronchitis only. Kilpelainen
et al.8 reported the results of a study validating a
questionnaire on respiratory symptoms in Finland
against ‘‘current asthma’’ (symptoms suggestive of
asthma during the preceding year at interview by
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Wheezing with attacks of shortness of breath
showed a high specificity (93%) and PPV (42%) but
a very low sensitivity (45%) due to the inclusion of
BHR in their definition of current asthma.
New Zealand, with Australia, United States and
Britain has a high rate of BHR compared to other
countries in Europe.9 In our study, BHR alone occurs
in 85% of diagnosed asthmatics but is also found in
20% of those without a diagnosis. This rate of ‘‘non-
asthmatic hyperreactivity’’ may be due to a pre-
asthmatic state10 suggesting asymptomatic airway
inflammation,11 to gastroesophageal reflux,12 to
other clinical situations like early chronic obstruc-
tive disease.13
When combining respiratory symptoms and BHR
(Table 2), we have a significantly higher specificity
and a lower sensitivity for asthma compared to the
respiratory symptoms alone. However, when com-
paring symptoms alone with symptoms plus BHR the
improvements in specificity are at the expense of
sensitivity.
Arguably the most useful overall index of
diagnostic value is Youden’s index as this combines
sensitivity and specificity and is a summary esti-
mate of precision. A history of wheeze combined
with BHR gives the highest Youden’s index, 0.75.
However, wheeze with dyspnoea alone has an index
of 0.72 and wheeze alone, 0.70, making these two
symptoms the best predictors of a diagnosis of
asthma in young New Zealand adults. The gender
differences in the predictive power of NCT and the
chronic symptoms suggest that females with asth-
ma are more likely to report these symptoms than
males with asthma. Adding BHR to symptoms adds
little extra diagnostic value. What Youden’s index
tells us is that a history of wheezing will correctly
predict asthma in 70% of cases, with 6% false
positives (1-sensitvity) and 24% false negatives
(1-specificity). For wheeze with dyspnoea, 72% will
be correctly diagnosed, but with 18% false positives
and 10% false negatives.References
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